8-K filing — Vaxart, Inc. (VXRT)
Filed: 2026-08-25 AccNo: 0001437749-26-028916 Size: 148 KB Item 8.01: Other Events
Read original at edgarStocks · News reference
8-K filing — Vaxart, Inc. (VXRT)
Filed: 2026-07-28 AccNo: 0001437749-26-024560 Size: 152 KB Item 8.01: Other Events
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 28, 2026, 12:00 PM
- Checked
- Jul 28, 2026, 12:00 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Vaxart resolved a proxy contest by entering a cooperation agreement with a stockholder group. The company will appoint a mutually agreed independent director within 90 days and form new board committees focused on stockholder engagement and clinical/regulatory affairs. The stockholder group withdrew its director nominations in exchange for enhanced corporate governance measures.
Read original at globenewswire-incVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart is urging shareholders to vote for all six of its director nominees on the WHITE proxy card ahead of its July 16, 2026 Annual Meeting. The company highlights strategic progress on its oral vaccine pipeline, including Phase 2b COVID-19 trials and partnerships with Dynavax, while defending its board against dissident nominees it claims lack relevant biotech expertise. Vaxart has made multiple settlement offers to resolve the proxy contest.
Read original at globenewswire-inc